Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 5345
Gene Symbol: SERPINF2
SERPINF2
0.040 AlteredExpression group BEFREE It is concluded that not only the absence of alpha 2-antiplasmin but also a reduction in its plasma level to +/- 60% of normal may predispose to a hemorrhagic diathesis. 6177359 1982
Entrez Id: 5176
Gene Symbol: SERPINF1
SERPINF1
0.020 AlteredExpression group BEFREE It is concluded that not only the absence of alpha 2-antiplasmin but also a reduction in its plasma level to +/- 60% of normal may predispose to a hemorrhagic diathesis. 6177359 1982
Entrez Id: 2158
Gene Symbol: F9
F9
0.050 Biomarker group BEFREE Hemophilia B Chapel Hill is a mild hereditary hemorrhagic disorder in which the factor IX antigen is present in normal amounts but factor IX biological activity is markedly reduced. 6603618 1983
Entrez Id: 5340
Gene Symbol: PLG
PLG
0.040 GeneticVariation group BEFREE A new life-long hemorrhagic disorder due to excess plasminogen activator. 6681588 1983
Entrez Id: 5345
Gene Symbol: SERPINF2
SERPINF2
0.040 GeneticVariation group BEFREE alpha 2-Antiplasmin Enschede: dysfunctional alpha 2-antiplasmin molecule associated with an autosomal recessive hemorrhagic disorder. 2445779 1987
Entrez Id: 5340
Gene Symbol: PLG
PLG
0.040 Biomarker group BEFREE The residual plasminogen-binding properties do not protect against a hemorrhagic diathesis. 2445779 1987
Entrez Id: 5176
Gene Symbol: SERPINF1
SERPINF1
0.020 GeneticVariation group BEFREE alpha 2-Antiplasmin Enschede: dysfunctional alpha 2-antiplasmin molecule associated with an autosomal recessive hemorrhagic disorder. 2445779 1987
Entrez Id: 2158
Gene Symbol: F9
F9
0.050 Biomarker group BEFREE Hemophilia B Kashihara is a severe hemorrhagic disorder in which the factor IX antigen is present in normal amounts but factor IX biological activity is markedly reduced. 2753873 1989
Entrez Id: 5345
Gene Symbol: SERPINF2
SERPINF2
0.040 Biomarker group BEFREE alpha 2-Plasmin inhibitor is the most important physiological inhibitor of fibrinolysis; hence, its deficiency results in a severe hemorrhagic diathesis. 2572590 1989
Entrez Id: 7450
Gene Symbol: VWF
VWF
0.040 Biomarker group BEFREE Synergistic effect of storage pool deficient platelets and low plasma von Willebrand factor on the severity of the hemorrhagic diathesis in Hermansky-Pudlak syndrome. 8237996 1993
Entrez Id: 2158
Gene Symbol: F9
F9
0.050 GeneticVariation group BEFREE Sequencing the complete factor IX gene of 2 sisters with hemophilia B with different phenotypes and no family history of hemorrhagic diathesis revealed a common 5' splice site mutation in intron 3 (T6704C) in both and an additional missense mutation (I344T) in one. 10942410 2000
Entrez Id: 2778
Gene Symbol: GNAS
GNAS
0.300 Biomarker group CTD_human Genetic variation of the extra-large stimulatory G protein alpha-subunit leads to Gs hyperfunction in platelets and is a risk factor for bleeding. 11583302 2001
Entrez Id: 5340
Gene Symbol: PLG
PLG
0.040 Biomarker group BEFREE Plasma plasmin inhibitor (PI) is a physiological inhibitor of plasmin-mediated fibrinolysis and constitutes a hemostatic component in blood plasma; hence its deficiency results in a severe hemorrhagic diathesis. 12152655 2002
Entrez Id: 5345
Gene Symbol: SERPINF2
SERPINF2
0.040 Biomarker group BEFREE Plasma plasmin inhibitor (PI) is a physiological inhibitor of plasmin-mediated fibrinolysis and constitutes a hemostatic component in blood plasma; hence its deficiency results in a severe hemorrhagic diathesis. 12152655 2002
Entrez Id: 2153
Gene Symbol: F5
F5
0.020 GeneticVariation group LHGDN Factor V Arg2074Cys: a novel missense mutation in the C2 domain of factor V. 12038802 2002
Entrez Id: 2776
Gene Symbol: GNAQ
GNAQ
0.010 AlteredExpression group LHGDN Human platelet Galphaq deficiency is associated with decreased Galphaq gene expression in platelets but not neutrophils. 11848441 2002
Entrez Id: 1361
Gene Symbol: CPB2
CPB2
0.010 AlteredExpression group BEFREE Since TAFI represents a connection between coagulation and fibrinolysis, it can be expected that TAFI levels are altered in different thrombotic and hemorrhagic diseases. 12165290 2002
Entrez Id: 2158
Gene Symbol: F9
F9
0.050 GeneticVariation group BEFREE Hemophilia A and B, inherited as X-linked recessive traits, are the most common hereditary hemorrhagic disorders caused by a deficiency or dysfunction of coagulation factor VIII (FVIII) or FIX, respectively. 16276463 2005
Entrez Id: 2157
Gene Symbol: F8
F8
0.020 GeneticVariation group BEFREE Hemophilia A in its severe form is a life-threatening hemorrhagic disease that is caused by mutations in the factor VIII (FVIII) gene (symbol F8). 16091456 2005
Entrez Id: 50808
Gene Symbol: AK3
AK3
0.010 GeneticVariation group BEFREE Hemophilia A and B, inherited as X-linked recessive traits, are the most common hereditary hemorrhagic disorders caused by a deficiency or dysfunction of coagulation factor VIII (FVIII) or FIX, respectively. 16276463 2005
Entrez Id: 2155
Gene Symbol: F7
F7
0.300 Biomarker group CTD_human Intracellular readthrough of nonsense mutations by aminoglycosides in coagulation factor VII. 16706976 2006
Entrez Id: 2158
Gene Symbol: F9
F9
0.050 GeneticVariation group BEFREE Haemophilia A and B, inherited as X-linked recessive traits, are the most common hereditary hemorrhagic disorders caused by a deficiency or dysfunction of blood coagulation factor VIII (FVIII) and factor IX (FIX). 16684001 2006
Entrez Id: 9402
Gene Symbol: GRAP2
GRAP2
0.010 Biomarker group BEFREE Collectively, our data suggest that inhibition of p38 MAPK may be a possible therapeutic approach to alter viral-induced acute hemorrhagic diseases. 16786433 2006
Entrez Id: 10598
Gene Symbol: AHSA1
AHSA1
0.010 Biomarker group BEFREE Collectively, our data suggest that inhibition of p38 MAPK may be a possible therapeutic approach to alter viral-induced acute hemorrhagic diseases. 16786433 2006
Entrez Id: 1398
Gene Symbol: CRK
CRK
0.010 Biomarker group BEFREE Collectively, our data suggest that inhibition of p38 MAPK may be a possible therapeutic approach to alter viral-induced acute hemorrhagic diseases. 16786433 2006